Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

摘要

What is this review about? This review evaluated the benefits and harms of antiviral agents as pre-emptive treatment to prevent symptomatic cytomegalovirus (CMV) disease in all solid organ transplant recipients. Pre-emptive treatment is commenced when evidence of active CMV replication is found on routine surveillance. This review includes pre-emptive treatment versus placebo or treatment when symptomatic, pre-emptive treatment versus prophylaxis and different regimens of preemptive treatment.